Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells.

Peeters MJW, Dulkeviciute D, Draghi A, Ritter C, Rahbech A, Skadborg SK, Seremet T, Carnaz Simões AM, Martinenaite E, Halldórsdóttir HR, Andersen MH, Olofsson GH, Svane IM, Rasmussen LJ, Met Ö, Becker JC, Donia M, Desler C, Thor Straten P.

Cancer Immunol Res. 2019 Sep;7(9):1472-1484. doi: 10.1158/2326-6066.CIR-18-0841. Epub 2019 Jul 2.

PMID:
31266785
2.

Peripheral memory T cells specific for Arginase-1.

Martinenaite E, Ahmad SM, Svane IM, Andersen MH.

Cell Mol Immunol. 2019 Aug;16(8):718-719. doi: 10.1038/s41423-019-0231-3. Epub 2019 May 10. No abstract available.

PMID:
31076727
3.

High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals.

Holmström MO, Ahmad SM, Klausen U, Bendtsen SK, Martinenaite E, Riley CH, Svane IM, Kjær L, Skov V, Ellervik C, Pallisgaard N, Hasselbalch HC, Andersen MH.

Blood Cancer J. 2019 Jan 17;9(2):8. doi: 10.1038/s41408-018-0166-4.

4.

Spontaneous T-cell responses against Arginase-1 in the chronic myeloproliferative neoplasms relative to disease stage and type of driver mutation.

Jørgensen MA, Holmström MO, Martinenaite E, Riley CH, Hasselbalch HC, Andersen MH.

Oncoimmunology. 2018 Jul 23;7(9):e1468957. doi: 10.1080/2162402X.2018.1468957. eCollection 2018.

5.

Frequent adaptive immune responses against arginase-1.

Martinenaite E, Mortensen REJ, Hansen M, Orebo Holmström M, Munir Ahmad S, Grønne Dahlager Jørgensen N, Met Ö, Donia M, Svane IM, Andersen MH.

Oncoimmunology. 2017 Dec 26;7(3):e1404215. doi: 10.1080/2162402X.2017.1404215. eCollection 2018.

6.

The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy.

Ahmad SM, Martinenaite E, Holmström M, Jørgensen MA, Met Ö, Nastasi C, Klausen U, Donia M, Pedersen LM, Munksgaard L, Ødum N, Woetmann A, Svane IM, Andersen MH.

Oncoimmunology. 2017 Nov 1;7(2):e1390641. doi: 10.1080/2162402X.2017.1390641. eCollection 2018.

7.

The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy.

Holmström MO, Martinenaite E, Ahmad SM, Met Ö, Friese C, Kjær L, Riley CH, Thor Straten P, Svane IM, Hasselbalch HC, Andersen MH.

Leukemia. 2018 Feb;32(2):429-437. doi: 10.1038/leu.2017.214. Epub 2017 Jul 5.

PMID:
28676668
8.

CCL22-specific T Cells: Modulating the immunosuppressive tumor microenvironment.

Martinenaite E, Munir Ahmad S, Hansen M, Met Ö, Westergaard MW, Larsen SK, Klausen TW, Donia M, Svane IM, Andersen MH.

Oncoimmunology. 2016 Sep 30;5(11):e1238541. doi: 10.1080/2162402X.2016.1238541. eCollection 2016.

9.

The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms.

Holmström MO, Hjortsø MD, Ahmad SM, Met Ö, Martinenaite E, Riley C, Straten P, Svane IM, Hasselbalch HC, Andersen MH.

Leukemia. 2017 Feb;31(2):495-498. doi: 10.1038/leu.2016.290. Epub 2016 Oct 20. No abstract available.

PMID:
27761006
10.

PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine.

Munir Ahmad S, Martinenaite E, Hansen M, Junker N, Borch TH, Met Ö, Donia M, Svane IM, Andersen MH.

Oncoimmunology. 2016 Jul 1;5(8):e1202391. doi: 10.1080/2162402X.2016.1202391. eCollection 2016 Aug.

11.

Spontaneous presence of FOXO3-specific T cells in cancer patients.

Larsen SK, Ahmad SM, Idorn M, Met Ö, Martinenaite E, Svane IM, Straten PT, Andersen MH.

Oncoimmunology. 2014 Nov 14;3(8):e953411. eCollection 2014.

Supplemental Content

Loading ...
Support Center